Innovation Pharmaceuticals Inc. Share Price

Equities

IPIX

US45782D1000

Biotechnology & Medical Research

Market Closed - OTC Markets 08:34:10 30/04/2024 pm IST 5-day change 1st Jan Change
0.0015 USD -40.00% Intraday chart for Innovation Pharmaceuticals Inc. -57.14% -69.39%
Sales 2022 0.02 1.5 Sales 2023 - Capitalization 10.37M 865M
Net income 2022 -7M -584M Net income 2023 -3M -250M EV / Sales 2022 67,33,26,722 x
Net cash position 2022 2.52M 210M Net cash position 2023 793K 66.17M EV / Sales 2023 -
P/E ratio 2022
-2.22 x
P/E ratio 2023
-3.19 x
Employees 4
Yield 2022 *
-
Yield 2023
-
Free-Float 87.87%
More Fundamentals * Assessed data
Dynamic Chart
Innovation Pharmaceuticals Inc. Announces Resignation of Board Members CI
Alfasigma S.p.A. and Innovation Pharmaceuticals Inc. Terminate Exclusive License Agreement CI
Innovation Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023 CI
Innovation Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Innovation Pharmaceuticals Provides Update on U.S. Patent Applications Covering Use of Brilacidin in Inflammatory Bowel Diseases, Coronaviruses and Fungal Diseases CI
Innovation Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023 CI
Innovation Pharmaceuticals Announces New Antifungal Testing of Brilacidin by NIH/NIAID Affiliated and Other Academic Researchers CI
Innovation Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022 CI
Innovation Pharmaceuticals Provides an Update on Ongoing Research on the Broad-Spectrum Antifungal Activity of Brilacidin CI
Innovation Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended September 30, 2022 CI
Innovation Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended June 30, 2022 CI
Innovation Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt CI
Innovation Pharmaceuticals Inc. acquired an unknown minority stake in Squalus Medical. CI
Squalus Medical announced that it has received $4.999968 million in funding from Innovation Pharmaceuticals Inc., and other investors CI
Innovation Pharmaceuticals Inc. announced a financing transaction CI
More news
1 day-40.00%
1 week-57.14%
Current month-89.51%
1 month-89.29%
3 months-78.57%
6 months-81.71%
Current year-69.39%
More quotes
1 week
0.00
Extreme 0.0001
0.00
1 month
0.00
Extreme 0.0001
0.02
Current year
0.00
Extreme 0.0001
0.02
1 year
0.00
Extreme 0.0001
0.02
3 years
0.00
Extreme 0.0001
0.54
5 years
0.00
Extreme 0.0001
0.65
10 years
0.00
Extreme 0.0001
4.93
More quotes
Managers TitleAgeSince
Chief Executive Officer 66 20/07/20
Chief Tech/Sci/R&D Officer 55 01/16/01
Members of the board TitleAgeSince
Chief Executive Officer 66 20/07/20
More insiders
Date Price Change Volume
30/24/30 0.0015 -40.00% 200
29/24/29 0.0025 -16.67% 102,000
26/24/26 0.003 +50.00% 161,805
25/24/25 0.002 -20.00% 204,500
24/24/24 0.0025 -28.57% 467,101

Delayed Quote OTC Markets, April 30, 2024 at 08:34 pm IST

More quotes
Innovation Pharmaceuticals Inc. is a clinical stage pharmaceutical company developing therapies with anti-infective, oncology, anti-inflammatory and dermatology applications. The Company’s lead drug candidate, Brilacidin, is in a class of compounds called defensin-mimetics, small compounds that mimic the structure and function of defensins, also known as host defense peptides. The Company is primarily focused on business development for the advancement of Brilacidin in the treatment of infectious diseases and oral mucositis. Its ongoing activities include Brilacidin drug manufacturing, scientific report writing, and supportive research activities. Brilacidin is also developed as a treatment in more extensive forms of inflammatory bowel disease (IBD). It is engaged in developing an image guided surgical laser platform, through BT BeaMedical Technologies Ltd. It is also engaged in business development and licensing initiatives with specialty and global pharmaceutical companies.
More about the company